Cocrystal Pharma Inc Stock Price, News & Analysis

Cocrystal Pharma (Nasdaq: COCP) completed a private placement on October 30, 2025 raising $1.03 million by selling 743,024 common shares at $1.39 per unit and issuing unregistered warrants to buy up to 1,486,048 shares at an exercise price of $1.24. The warrants are exercisable upon issuance and expire in 27 months. Four investors were company insiders and directors, including Phillip Frost, Fred Hassan, Richard Pfenniger and co-CEO/CFO James Martin. If all warrants are exercised for cash, the company would receive approximately $1.83 million more. The company said net proceeds will support clinical development programs, working capital and general corporate purposes. The securities were offered under Section 4(a)(2) and Regulation D and are unregistered.

Cocrystal Pharma (Nasdaq: COCP) announced on October 27, 2025 that it received a NIH/NIAID SBIR Phase I award of approximately $500,000 to support development of a novel, oral, broad‑spectrum antiviral candidate for influenza A and B. The funds will be used to characterize lead molecules that inhibit an essential function of the influenza polymerase complex. The award is non‑dilutive and intended to assess scientific, technical and commercial potential; successful Phase I completion may enable application for a larger Phase II award. The research is supported under award number 75N93025C00038. Management highlighted the award as validation of its structure‑based drug discovery platform and part of a strategy to secure additional non‑dilutive capital.

Cocrystal Pharma (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025 at 12:00 pm Eastern time.

The presentation will include a company overview followed by a Q&A session. Investors can access the live presentation through registration, and a video webcast will be available on the company's website within 48 hours of the event, remaining accessible for 90 days. Additionally, Mr. Martin will be available for one-on-one meetings with qualified investors during the conference.

Cocrystal Pharma (Nasdaq: COCP) has closed its previously announced registered direct offering, raising $4.7 million through the sale of 2,764,710 shares at $1.70 per share. The offering was priced at-the-market under Nasdaq rules.

In a concurrent private placement, the company issued unregistered warrants to purchase up to 5,529,420 shares at an exercise price of $1.50 per share. If fully exercised, these warrants could generate additional gross proceeds of approximately $8.3 million. The warrants are exercisable immediately and expire in 24 months.

H.C. Wainwright & Co. served as the exclusive placement agent. Cocrystal plans to use the net proceeds for working capital and general corporate purposes.

Cocrystal Pharma (Nasdaq: COCP) has announced a registered direct offering priced at-the-market, consisting of 2,764,710 shares of common stock at $1.70 per share. The offering includes a concurrent private placement of unregistered warrants to purchase up to 5,529,420 shares at $1.50 per share, exercisable for 24 months.

The company expects to receive initial gross proceeds of $4.7 million, with potential additional proceeds of $8.3 million if all warrants are exercised. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is anticipated to close around September 15, 2025, with proceeds intended for working capital and general corporate purposes.

Cocrystal Pharma (Nasdaq: COCP) presented Phase 1 data for CDI-988, their lead pan-viral protease inhibitor and potential first oral antiviral for norovirus infection, at the 9th International Calicivirus Conference. The presentation highlighted CDI-988's favorable safety profile in human intestinal tissue and broad-spectrum antiviral activity against multiple norovirus genogroups.

The company recently received FDA clearance for its Investigation New Drug (IND) application to proceed with a Phase 1b human challenge study, expected to begin before year-end. The drug, developed using Cocrystal's proprietary structure-based platform technology, targets a highly conserved region in the active site of noroviruses and showed no serious adverse events in Phase 1 trials.

Cocrystal Pharma (Nasdaq: COCP) has received FDA clearance to proceed with a Phase 1b challenge study for CDI-988, their novel oral broad-spectrum protease inhibitor targeting norovirus infections. The study is expected to begin by year-end 2025.

CDI-988 represents a potential breakthrough as the first antiviral drug candidate for norovirus prevention and treatment, with no currently approved vaccines or therapeutics available. The drug has demonstrated broad-spectrum antiviral activity against major norovirus proteases including GII.4 and GII.17, and showed favorable safety in Phase 1 studies.

Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.

The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.

Cocrystal Pharma (Nasdaq: COCP) reported Q2 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988 showed favorable Phase 1 safety and tolerability results for norovirus treatment. A Phase 1b norovirus challenge study is planned for later in 2025.

Financial highlights include Q2 2025 net loss of $2.1 million ($0.20 per share), reduced from $5.3 million in Q2 2024. R&D expenses decreased to $1.1 million from $4.3 million year-over-year. The company reported $4.8 million in cash as of June 30, 2025.

CDI-988 demonstrated broad-spectrum activity against norovirus strains, including the prevalent GII.17 strains responsible for 2024-2025 outbreaks. The company's pipeline also includes CC-42344 for influenza treatment, which showed activity against highly pathogenic H5N1 avian influenza strains.